Eli Lilly Total Assets 2010-2023 | LLY

Eli Lilly total assets from 2010 to 2023. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Eli Lilly total assets for the quarter ending December 31, 2023 were $57.916B, a 22.03% increase year-over-year.
  • Eli Lilly total assets for 2022 were $49.49B, a 1.4% increase from 2021.
  • Eli Lilly total assets for 2021 were $48.806B, a 4.66% increase from 2020.
  • Eli Lilly total assets for 2020 were $46.633B, a 18.7% increase from 2019.
Eli Lilly Annual Total Assets
(Millions of US $)
2022 $49,490
2021 $48,806
2020 $46,633
2019 $39,286
2018 $43,908
2017 $44,981
2016 $38,806
2015 $35,569
2014 $36,308
2013 $35,249
2012 $34,399
2011 $33,660
2010 $31,001
2009 $27,461
Eli Lilly Quarterly Total Assets
(Millions of US $)
2023-09-30 $57,916
2023-06-30 $54,814
2023-03-31 $53,163
2022-12-31 $49,490
2022-09-30 $47,462
2022-06-30 $47,064
2022-03-31 $46,919
2021-12-31 $48,806
2021-09-30 $48,187
2021-06-30 $47,809
2021-03-31 $46,838
2020-12-31 $46,633
2020-09-30 $43,946
2020-06-30 $41,967
2020-03-31 $41,103
2019-12-31 $39,286
2019-09-30 $37,893
2019-06-30 $38,666
2019-03-31 $38,007
2018-12-31 $43,908
2018-09-30 $44,625
2018-06-30 $42,359
2018-03-31 $44,356
2017-12-31 $44,981
2017-09-30 $43,010
2017-06-30 $40,947
2017-03-31 $37,624
2016-12-31 $38,806
2016-09-30 $37,590
2016-06-30 $36,475
2016-03-31 $34,692
2015-12-31 $35,569
2015-09-30 $36,305
2015-06-30 $36,037
2015-03-31 $35,654
2014-12-31 $36,308
2014-09-30 $34,649
2014-06-30 $35,018
2014-03-31 $34,757
2013-12-31 $35,249
2013-09-30 $33,966
2013-06-30 $33,226
2013-03-31 $32,300
2012-12-31 $34,399
2012-09-30 $34,321
2012-06-30 $31,813
2012-03-31 $32,238
2011-12-31 $33,660
2011-09-30 $33,042
2011-06-30 $32,779
2011-03-31 $31,695
2010-12-31 $31,001
2010-09-30 $29,904
2010-06-30 $27,723
2010-03-31 $27,198
2009-12-31 $27,461
2009-09-30 $27,128
2009-06-30 $26,932
2009-03-31 $26,597
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $743.142B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $557.486B 45.93
Johnson & Johnson (JNJ) United States $390.509B 15.54
Merck (MRK) United States $321.545B 84.64
AbbVie (ABBV) United States $316.040B 16.10
Novartis AG (NVS) Switzerland $216.326B 14.99
AstraZeneca (AZN) United Kingdom $200.284B 17.75
Pfizer (PFE) United States $150.148B 14.53
Sanofi (SNY) $119.624B 10.77
Innoviva (INVA) United States $0.977B 6.80